" class="no-js "lang="en-US"> Andrew Drechsler - Medtech Alert
Sunday, February 05, 2023
Andrew Drechsler

Andrew Drechsler

About Andrew Drechsler

CFO of Provention Bio with 25 years of financial and life science industry experience.

Responsibilities at Provention include leading the company’s financial activities, as well as collaborating with the executive team in the ongoing execution of a drug development strategy that sources, repositions and advances candidates that have been acquired or in-licensed because of their therapeutic potential to interrupt, delay, reverse or prevent the onset or progression of immune-mediated diseases.

Career highlights:
• Provention’s $64 million initial public offering (July 2018)
• Negotiated agreements with MacroGenics and Amgen, resulting in the addition of three products to Provention’s pipeline, including a Phase 3 program for the interception of type-one diabetes
• Raised more than $400 million at Insmed through equity offerings
• Secured $200 million in U.S. government funding for VaxInnate Corporation in addition to raising over $40 million in venture capital
• Led Valera Pharmaceuticals initial public offering and eventual sale to Indevus (now Endo)

Related Story

Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer

November 4 2021

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today […]